Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Invigor Medical vs Care Clinics

Two GLP-1 desks, one scoreboard. We put Invigor Medical and Care Clinics head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 9 · Grade B+

Invigor Medical

Visit Invigor Medical Full brief →
vs
No. 130 · Grade C

Care Clinics

Visit Care Clinics Full brief →

The verdict

Invigor Medical takes this head-to-head.

Invigor Medical scores 88 to 70 on our six-factor Brief Score — An established telehealth pharmacy with a broad metabolic and hormone catalog and a steady price line.

That doesn't make Care Clinics a bad call — it's best for readers who want multi-duration glp-1 programs from a named legitscript-certified pllc. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
87
46
Supply Reliability
88
75
Transparency
84
88
Access Breadth
82
74
Clinical Oversight
88
68
Track Record
90
77
Invigor MedicalBrief Score 88 · 70Care Clinics

Price, coverage & the tracker

Invigor MedicalCare Clinics
Brief Score88/100 (B+)70/100 (C)
Semaglutide$199/moFrom $100/mo (3-month plan, compounded)
Tirzepatide$339/moFrom $133/mo (3-month plan, compounded)
CoverageNot disclosed32 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Invigor Medical: Long-running operator; mid-market pricing unchanged this cycle.

Care Clinics: New to the tracker on 1 August 2026. The published line reads From $100/mo (3-month plan, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.